Navidea Biopharmaceuticals Inc.
NAVB
NAVB was delisted on the 5th of October, 2023.
52 hedge funds and large institutions have $7.5M invested in Navidea Biopharmaceuticals Inc. in 2017 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 14 increasing their positions, 10 reducing their positions, and 2 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 10
0% more funds holding
Funds holding: 52 → 52 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
14% less capital invested
Capital invested by funds: $8.72M → $7.5M (-$1.22M)
30% less call options, than puts
Call options by funds: $30K | Put options by funds: $43K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
+$125K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$120K |
| 3 |
Jane Street
New York
|
+$47.5K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$39.8K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$24.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$325K |
| 2 |
Millennium Management
New York
|
-$102K |
| 3 |
SIM
Spark Investment Management
New York
|
-$69.5K |
| 4 |
Goldman Sachs
New York
|
-$23.6K |
| 5 |
SFS
Sowell Financial Services
North Little Rock,
Arkansas
|
-$22K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CPIG
51
Chicago Partners Investment Group
Chicago,
Illinois
| – | -$2K | -174 | Closed |
|
52
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$1K | -45 | Closed |
|
NAVB Hedge Fund Activity: Q2 2017 in Review
52 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q2 2017, worth a combined $7.5M — down 14% from $8.72M a quarter earlier.
Fund positioning in NAVB was balanced in Q2 2017: 2 funds opened new positions, 2 closed out, 14 added to existing stakes and 10 trimmed.
The largest buyer was Virtu KCG Holdings, adding an estimated $125K. The largest seller was BlackRock, cutting an estimated $325K.
- 52 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q2 2017, unchanged from Q1 2017.
- Funds reported $7.5M of Navidea Biopharmaceuticals Inc. stock for Q2 2017, down 14% quarter-over-quarter.
- 2 funds opened new Navidea Biopharmaceuticals Inc. positions in Q2 2017 and 2 closed out, a net change of 0 holders.
- The largest Navidea Biopharmaceuticals Inc. buyer in Q2 2017 was Virtu KCG Holdings, an estimated $125K added.
- The largest Navidea Biopharmaceuticals Inc. seller in Q2 2017 was BlackRock, an estimated $325K sold.
Based on aggregated 13F filings for Q2 2017.